Eikon Therapeutics, Inc. logo
EIKN

Eikon Therapeutics, Inc.

Last Price US$10.58 Latest stored quote
Market Cap US$572.8m Company size context
7D Performance -15.63% Past 7 days
1Y Performance N/A Past 12 months
Model Rating Not rated Insufficient reported history for the model
Loading Mave Thesis research outlook

Dashboard Funda..tals Prediction Screener Map

Eikon Therapeutics, Inc. Overview

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Sector: Health Care

Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of hig Read More

Newly listed company coverage

Verified company profile, price history, and SEC registration source are available.

10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.

Review the SEC registration filing

Reported Results

No latest earnings report cached yet

Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

Recent News



Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Annual 10-K/20-F financial statement data is not available yet.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc.

US$10.58

US$572.8m

-15.63%

N/A